NCT03095092 is a Phase 1 clinical trial of BIA 6-512 400 mg in Parkinson Disease, sponsored by Bial - Portela C S.A..

Who is sponsoring NCT03095092?

NCT03095092 is sponsored by Bial - Portela C S.A..

What drugs are being tested in NCT03095092?

Interventions in NCT03095092: BIA 6-512 400 mg.

What condition does NCT03095092 study?

NCT03095092 studies Parkinson Disease.

Is NCT03095092 still recruiting?

NCT03095092 is currently completed. Last updated 29 March 2017.

Last reviewed 2017-03-29 · How we verify

NCT03095092

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Food on BIA 6-512 (Trans-resveratrol)

Completed Phase 1 Last updated 29 March 2017

What this trial tests

Phase 1 trial testing BIA 6-512 400 mg in Parkinson Disease in 24 participants. Completed in 7 July 2005.

Timeline

23 May 2005

Primary endpoint
7 July 2005

7 July 2005

Quick facts

Lead sponsor	Bial - Portela C S.A.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	23 May 2005
Primary completion	7 July 2005
Estimated completion	7 July 2005
Sites	1 location across Portugal

Drugs / interventions tested

BIA 6-512 400 mg — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Bial - Portela C S.A. — full company profile →

Who can join

Adults 18 to 45, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study was to investigate the effect of food on the pharmacokinetics of a single 400 mg dose of BIA 6-512 (trans-resveratrol) in healthy volunteers

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson's Disease.
Kung HC, Lin KJ, Kung CT, Lin TK. · · 2021 · cited 85× · PMID 34440122 · DOI 10.3390/biomedicines9080918
Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction.
Yadav E, Yadav P, Khan MMU, Singh H, et al · · 2022 · cited 38× · PMID 36188541 · DOI 10.3389/fphar.2022.922232
Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease.
Bonam SR, Tranchant C, Muller S. · · 2021 · cited 34× · PMID 34944054 · DOI 10.3390/cells10123547
The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1.
Fledderus J, Vanchin B, Rots MG, Krenning G. · · 2021 · cited 19× · PMID 33562658 · DOI 10.3390/jpm11020103
Stilbenes: a promising small molecule modulator for epigenetic regulation in human diseases.
Tian J, Jin L, Liu H, Hua Z. · · 2023 · cited 12× · PMID 38155902 · DOI 10.3389/fphar.2023.1326682
Role of histone deacetylase inhibitors in non-neoplastic diseases.
Zhou C, Zhao D, Wu C, Wu Z, et al · · 2024 · cited 10× · PMID 39071622 · DOI 10.1016/j.heliyon.2024.e33997

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Bial - Portela C S.A. trials

Trials by the same sponsor.

NCT07403799 — REal-life ON PARKinson's - ITaly (REONPARK-IT) · recruiting
NCT04990284 — eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. · Phase 4 · completed
NCT04986995 — OpicApone Sleep dISorder · Phase 4 · completed
NCT04978597 — Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) · Phase 3 · completed
NCT04986982 — OpiCapone Effect on Motor Fluctuations and pAiN · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03095092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bial - Portela C S.A.
Last refreshed: 29 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03095092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing